stockrowAgios Pharmaceuticals, Inc.
AGIO Healthcare Biotechnology
Agios Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $54.0 million, up 48.0% from fiscal 2024.
- Revenue
- +330.0%
- EPS
- +38.8%
- Free cash flow
- +32.6%
Quarter to September 2026, against a year earlier
Follow AGIO
Alert me
Agios Pharmaceuticals, Inc. (AGIO) EV/Sales
As of 6 November 2026, Agios Pharmaceuticals, Inc. (AGIO) trades at a EV/Sales of 7.9×. Over the past ten years it has ranged from 0.1× (June 2022) to 115× (June 2018); the current reading is higher than 11% of that period. That is below the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 13.4× | (49.76%) |
| FY2024 | 26.7× | 44.83% |
| FY2023 | 18.4× | (63.86%) |
| FY2022 | 50.9× | 328.31% |
| FY2020 | 11.9× | (39.03%) |
| FY2019 | 19.5× | (10.70%) |
| FY2018 | 21.8× | (60.24%) |
| FY2017 | 54.9× | 234.03% |
| FY2016 | 16.5× | (53.97%) |
| FY2015 | 35.7× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 9.6× | (40.49%) |
| Jun 2026 | 16.2× | (14.67%) |
| Mar 2026 | 19.0× | 41.47% |
| Dec 2025 | 13.4× | (56.55%) |
| 39 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| NRIX Nurix Therapeutics, Inc. compare | 0.9× |
| NVAX Novavax, Inc. compare | 3.3× |
| AGIO Agios Pharmaceuticals, Inc. | 7.9× |
| ZBIO Zenas BioPharma, Inc. compare | 23.5× |
| GENB Generate Biomedicines, Inc. compare | 37.2× |
| STOK Stoke Therapeutics, Inc. compare | 52.8× |
| SLS SELLAS Life Sciences Group, Inc. compare | 136× |
| ABSI Absci Corporation compare | 896× |
| LYCA Lycia Therapeutics Inc. compare | — |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)